48
Participants
Start Date
September 8, 2022
Primary Completion Date
June 25, 2024
Study Completion Date
January 9, 2025
RXC007
RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
Placebo
The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
Medical University of Vienna, Vienna
E PNE UZ Leuven, Leuven
CHU De Liège, Liège
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Ospedale S. Giuseppe Milano, Milan
Hospital Universitario La Paz, Madrid
Hospital Universitario Central de Asturias, Oviedo
Azienda Ospedaliera Universitaria Integrata Verona, Verona
Hospital Universitario Marqués de Valdecilla, Santander
Azienda Ospedaliera Universitaria of Modena, Modena
"Azienda Ospedaliero-Universitaria Ospedali-Riuniti di Ancona", Ancona
Colonello D'avanzo Hospital, Foggia
PO Vito Fazzi, Lecce
Azienda Ospedaliero Universitaria Policlinico ''G.Rodolico-San Marco'', Catania
Pneumologicka klinika 1.LF UK a, Prague
Fondazione Policlinico Universitario A. Gemelli, Roma
University Clinical Centre in Gdansk, Gdansk
Institute of Tuberculosis and Lung Diseases in Warsaw, Warsaw
Barlicki University Hospital, Lodz
University Hospital of Geneve, Geneva
Policlinica Barcelona, Barcelona
Hospital Universitario Clínic de Barcelona, Barcelona
L'Hospital Universitari de Bellvitge, Barcelona
Belfast City Hospital, Belfast
Queen Elizabeth Hospital, Birmingham
Royal Papworth Hospital NHSFT, Cambridge
Royal Infirmary of Edinburgh, Edinburgh
Guy's Hospital, London
Royal Brompton Hospital, London
Altnagelvin Area Hospital, Londonderry
Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford
Collaborators (1)
Simbec-Orion Group
INDUSTRY
Redx Pharma Ltd
INDUSTRY